- In December 2024, a phase II study evaluated the combination of ibrutinib and ixazomib in patients with newly diagnosed and relapsed/refractory WM. The study demonstrated a 76.2% overall response rate and a median progression-free survival of 22.9 months, indicating the potential of combining Bruton's tyrosine kinase inhibition with proteasome inhibition in WM treatment
- At the 2024 American Society of Hematology (ASH) Annual Meeting, long-term data from the ASPEN trial revealed that zanubrutinib, a Bruton's tyrosine kinase inhibitor, offers superior tolerability and sustained efficacy compared to ibrutinib in patients with WM, including those with MYD88 wild-type mutations. This positions zanubrutinib as a promising alternative for WM patients
- In December 2024, a study presented at ASH 2024 reported on the two-year follow-up of treatment-naive WM patients who had previously received a combination of ibrutinib and venetoclax. The follow-up data indicated that the combination therapy led to durable responses, although the study was halted due to safety concerns, including ventricular arrhythmia events.
